Rodman & Renshaw initiated coverage of Hemab Therapeutics (NASDAQ: COAG) with a “buy” rating and price target of $56.00. The stock closed at $31.62 on October 9.
Hemab’s lead asset sutacimig is a bispecific antibody that binds TLT-1, a receptor found only on activated platelets, to deliver endogenous factor VIIa to the site of vascular injury. In Glanzmann thrombasthenia, where no prophylactic therapy is approved anywhere, the Phase 1/2 long-term extension showed an 87% reduction in annualized treated bleed rate at the best-performing dose cohort. Among patients with a life-threatening bleed in the prior 12 months, those events fell 100%, and 29% of evaluable patients eliminated treated bleeds entirely. The FDA has granted Breakthrough Therapy, Fast Track, and Orphan Drug designations. It has also aligned with Hemab on the Phase 3 dose and design. A Phase 2b study in Factor VII deficiency extends the molecule into a second indication.
Behind sutacimig sits HMB-002, a monovalent antibody that rescues circulating Von Willebrand factor from clearance. It targets roughly 120,000 patients across Hemab’s core markets, an order of magnitude beyond Glanzmann thrombasthenia and Factor VII deficiency combined. In VELORA Pioneer, the 150 mg cohort raised VWF antigen and Factor VIII at least 2.4-fold, and eight of nine evaluable patients had zero treated bleeds in the four weeks after a single injection. A third program, HMB-003, has just entered the clinic. It addresses heavy menstrual bleeding with a long-acting, non-hormonal antifibrinolytic peptide that blocks plasmin to stop clots from breaking down prematurely. More than 23 million US women are affected, and the only approved non-hormonal treatment requires multiple daily doses throughout menses.
“Hemab trades at approximately $1.48 billion in market capitalization, implying meaningful upside even before ascribing any value to label expansion or branching into other indications,” writes Rodman & Renshaw analyst Michael G. King, Jr.
“Compare that to BioMarin (BMRN, NC), the closest thing rare hematology and enzyme-replacement investors have to a category bellwether, which commands a market capitalization north of $12.9 billion on the back of a portfolio of approved, revenue-generating rare disease therapies. Hemab is earlier stage by definition, but the read-through is instructive: the market has shown it will pay a substantial multiple for durable, prophylactic rare disease franchises once clinical risk clears, and sutacimig’s Phase 3 initiation this year represents exactly that risk-clearing event for the most advanced asset in the portfolio. uniQure (QURE, NC), another rare-disease-focused peer building toward gene therapy approvals in neurological indications, trades near $3.2 billion, again suggesting that specialty biotech investors reward differentiated mechanisms with real clinical validation well before commercial launch,” he adds.
